Home
>
US Stocks
>
TG Therapeutics Inc
TG Therapeutics Inc
TGTX

TG Therapeutics Inc

$32.9230.63%

1D

1W

1M

1Y

3Y

5Y

Key Stats

Open
33.22
Today Low/High
32.72 / 33.59
52 Week Low/High
$21.06 / $56.74
P/E ratio
-9.1573
Market Cap
$3.15B

Company Details

TG Therapeutics is a fully-integrated, commercial stage biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. In addition to an active research pipeline including five investigational medicines across these therapeutic areas, TG has received accelerated approval from the U.S. FDA for UKONIQTM (umbralisib), for the treatment of adult patients with relapsed/refractory marginal zone lymphoma who have received at least one prior anti-CD20-based regimen and relapsed/refractory follicular lymphoma who have received at least three prior lines of systemic therapies. Currently, the Company has two programs in Phase 3 development for the treatment of patients with relapsing forms of multiple sclerosis (RMS) and patients with chronic lymphocytic leukemia (CLL) and several investigational medicines in Phase 1 clinical development.
Organisation
TG Therapeutics Inc
Headquaters
New York, New York, US
Employees
272
Industry
Health Technology
CEO
Michael Weiss

Discover more

Frequently Asked Questions

What is TG Therapeutics Inc share price today

Can Indians buy TG Therapeutics Inc shares?

How can I buy TG Therapeutics Inc shares from India?

Can Fractional shares of TG Therapeutics Inc be purchased?

What are the documents required to start investing in TG Therapeutics Inc stocks?

We are a SEBI registered investement advisor